ClinicalTrials.gg
RecruitingNCT04850456Updated Mar 16, 2026

Treatment Strategy of Human Gamma Globulin on the Therapy for Intensively Ill Children With Inflammatory Storm

An observational study in Critical Illness and Sepsis, Severe, sponsored by Children's Hospital of Fudan University. Recruiting at 2 sites in China. Open to participants aged 29 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Primary conditionSepsisRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sepsis
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Children's Hospital of Fudan University · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
29 Days to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Sepsis by Children's Hospital of Fudan University — 6 open to participants now, 6 under way, none of them phase 3. Sepsis · Children's Hospital of Fudan University.

Started
2024
the only one that year
Observational
9 of 10
5 open now
Registered
3rd of 10
by date

Among the 10 studies in Sepsis by Children's Hospital of Fudan University, this one is the only one that started in 2024, is one of 9 observational ones, and was the 3rd registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

6 of the 10 studies in Sepsis by Children's Hospital of Fudan University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 29 Days to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Sepsis by Children's Hospital of Fudan University, or all of them as a file.
02

Study summary

The inflammatory storm in critically ill patients releases cytokines, causing systemic immune damage, which may be an important cause of multiple organ failure and even death. Inflammatory storms exacerbate the deterioration of the disease in those children. Gamma globulin may be an effective option to control inflammatory storms. However, this preliminary result needs to be verified from reliable and representative RCTs. In our study, we conducted a retrospective study on the use of gamma globulin and an unused control group. At present, the indications of IVIG are mainly focused on the neuromuscular system and the blood system. We hope to establish a more appropriate and operable evaluation table for the suitability of gamma globulin for clinical use.

Read the detailed description

In severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe secondary hospital-acquired infections. However, the role of gamma globulin therapy in patients with severe infection including sepsis and septic shock is discussed controversially. We intend to retrospectively analyze the efficacy and application evaluation of gamma globulin in severely infected children hospitalized in the intensive care unit. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record. It is expected to provide evaluation basis for clinicians to formulate treatment plans and clinical pharmacists for special comments on the clinical use of gamma globulin.

03

Conditions studied

  • Critical Illness
  • Sepsis, Severe

Browse trials for

Keywords

  • Sepsis
  • Critical Illness
  • Inflammatory Storm
  • Gamma Globulin
04

In context

Sepsis Reclassified

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

This study's planned enrollment of 200 is above the median of 150 across 1,166 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 94 are open to participants now.

Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
29 Days to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All children hospitalized in PICU of Children's Hospital of Fudan University from January 2022 to December 2023

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children hospitalized in PICU of Children's Hospital of Fudan University
  • Children With Severe Infection Complicated With Inflammatory Storm

Exclusion criteria

Exclusion Criteria:

  • discharge within 48 hours
  • patients without
  • incomplete clinical and demographic data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • trial group

    Human Gamma Globulin

  • control group

    conventional treatment

07

What researchers measure

Primary outcomes

  1. The death rate of children

    The death rate of children in 28 days after their discharged from PICU

    Time frame: within 28 days after they discharged from PICU

  2. length of stay in PICU

    Time from PICU admission to discharge

    Time frame: up to 28 days

Secondary outcomes

  1. CD4+/CD8+

    levels of peripheral blood subgroup of T lymphocyte (digital form)

    Time frame: Within 3 to 15 days after the start of treatment

  2. C-reactive protein (CRP)

    C-reactive protein (digital form)

    Time frame: Within 3 to 15 days after the start of treatment

  3. IL-2R

    The interleukin-2 receptor (digital form)

    Time frame: Within 3 to 15 days after the start of treatment

  4. TNF-alpha

    Tumor necrosis factor alpha (digital form)

    Time frame: Within 3 to 15 days after the start of treatment

  5. Treg

    levels of peripheral blood subgroup of T lymphocyte (digital form)

    Time frame: Within 3 to 15 days after the start of treatment

  6. IL-6

    The interleukin-6 (digital form)

    Time frame: Within 3 to 15 days after the start of treatment

  7. IFN-gamma

    Interferon gamma (digital form)

    Time frame: Within 3 to 15 days after the start of treatment

  8. Procalcitonin (digital form)

    Procalcitonin (digital form)

    Time frame: Within 3 to 15 days after the start of treatment

  9. IL-10

    The interleukin-10 (digital form)

    Time frame: Within 3 to 15 days after the start of treatment

08

Study locations

2 of 2 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2021
First posted
Apr 20, 2021
StartActual
Oct 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04850456
Responsible party
Sponsor
First posted
Apr 20, 2021
Start date
Oct 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 16, 2026

Study contacts

Guoping Lu, Doctor
Contact
13788904150@163.com
13788904150
Yao Wang
Contact
y_wang@fudan.edu.cn
+86 13636547582

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion